Arévalo MFG

Language: Spanish
References: 20
Page: 161-163
PDF size: 142.06 Kb.

Text Extraction

No abstract

REFERENCES

1. LeRoy EC, Black C, Fleishmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202.

2. Fleishmajer R, Damiano V, Nedwich A. Alteration of subcutaneous tissue in systemic scleroderma. Arch Dermatol 1972; 105: 59.

3. Haynes DC, Gershwin ME. The immunopathology of progressive systemic sclerosis. Semin Arthritis Rheum 1982; 11: 331.

4. Silver RM, Miller KS, Kinsella MB et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470.

5. Steen VD, Medsger TA Jr, Rodman GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma) a retrospective analysis. Ann Int Med 1982; 97: 652-659.

6. Adnan ZA. Diagnosis and treatment of scleroderma. Acta Med Indones 2008; 40(2): 109-12.

7. Amjad S, Maranian P, Clments PJ, Wonk WK, Postlethwaite AE, Khanna PP. Course of the modified Rodnan score in systemic sclerosis clinical trials: analysis of three large multicenter, double blind, randomized controlled trials. Investigators of the D-penicillamine, human recombinant relaxin, and oral bovine type I collagen clinical trials. Arthritis Rheum 2009; 60(8): 2490-8.

8. Alarcon-Segovia D. Progressive systemic sclerosis: management. Part IV. Colchicine. Clin Rheum Dis 1979; 5: 294-302.

9. Ostojic P, Damjanov N. Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy. Clin Rheumatol 2006: 1-3.

10. Valentini G, Paone C, La Montagna G et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006; 35(1): 35-38.

11. Dheda K, Lalloo UG, Cassim B et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23(4): 306-309.

12. Nadashkevich O, Davis P, Fritzler M et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 206; 25(2): 205-212.

13. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006.

14. Swigris JJ, Olson AL, Fischer A et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130(1): 30-36.

15. Barst RJ, Gibbs J, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (Suppl): S78-84.

16. Zierer A, Voeller RK, Melby SJ, Steendijk P, Moonm MR. Impact of calcium-channel blockers on right heart function in a controlled model of chronic pulmonary hypertension. Eur J Anaesthesiol 2009; 20(3): 253-9.

17. Rigau D, Agusti A. Tratamiento de la hipertensión arterial pulmonar primaria con fármacos con efecto vasodilatador. Med Clin (Barc) 2003; 120(5): 194-6.

18. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with sclerosis systemic. Arthritis Rheum 2007; 56: 1985-93.

19. Sott LJ. Sitaxentan in pulmonary arterial hypertension. Drugs 2007; 7: 61-70.

20. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-53.